{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mirabegron+25+MG",
    "query": {
      "intervention": "Mirabegron 25 MG"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mirabegron+25+MG&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T09:13:26.306Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05880862",
      "title": "Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Urinary Bladder, Overactive",
        "Urinary Incontinence",
        "Accidental Falls"
      ],
      "interventions": [
        {
          "name": "Pelvic Floor Muscle Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Trospium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 99 Years · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2023-09-28",
      "completion_date": "2025-12-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05880862"
    },
    {
      "nct_id": "NCT06133075",
      "title": "Using Mirabegron to Increase BP in Patients With POTS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postural Orthostatic Tachycardia Syndrome",
        "Chronic Orthostatic Intolerance",
        "Syncope"
      ],
      "interventions": [
        {
          "name": "Mirabegron 50 MG",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron 25 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-12-22",
      "completion_date": "2025-07-25",
      "has_results": true,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06133075"
    },
    {
      "nct_id": "NCT04666636",
      "title": "Mechanisms for Activation of Beige Adipose Tissue in Humans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PreDiabetes"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron 50 MG",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip Kern",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 65,
      "start_date": "2020-12-07",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666636"
    },
    {
      "nct_id": "NCT00912964",
      "title": "A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder, Overactive"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2030,
      "start_date": "2009-04-28",
      "completion_date": "2010-04-27",
      "has_results": true,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 82,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912964"
    },
    {
      "nct_id": "NCT05806164",
      "title": "Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urgency Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]",
          "type": "DRUG"
        },
        {
          "name": "OnabotulinumtoxinA 100 UNT [Botox]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Women and Infants Hospital of Rhode Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 432,
      "start_date": "2023-06-06",
      "completion_date": "2030-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05806164"
    },
    {
      "nct_id": "NCT02138747",
      "title": "A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder (OAB)"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 376,
      "start_date": "2014-07-24",
      "completion_date": "2015-11-11",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 22,
      "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138747"
    },
    {
      "nct_id": "NCT01908829",
      "title": "A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder Diseases",
        "Urinary Bladder Overactive",
        "Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "mirabegron 25 mg",
          "type": "DRUG"
        },
        {
          "name": "mirabegron 50 mg",
          "type": "DRUG"
        },
        {
          "name": "solifenacin 5 mg",
          "type": "DRUG"
        },
        {
          "name": "solifenacin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "mirabegron 25 mg matching placebo",
          "type": "DRUG"
        },
        {
          "name": "mirabegron 50 mg matching placebo",
          "type": "DRUG"
        },
        {
          "name": "solifenacin 5 mg matching placebo",
          "type": "DRUG"
        },
        {
          "name": "solifenacin 10 mg matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Europe Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2174,
      "start_date": "2013-07-10",
      "completion_date": "2014-11-25",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Valley Village",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01908829"
    },
    {
      "nct_id": "NCT03817931",
      "title": "Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder",
        "Dementia",
        "Lower Urinary Tract Symptoms",
        "Incontinence, Urge"
      ],
      "interventions": [
        {
          "name": "Anticholinergic",
          "type": "DRUG"
        },
        {
          "name": "Beta-3 Agonists, Adrenergic",
          "type": "DRUG"
        },
        {
          "name": "Functional magnetic resonance imaging (fMRI)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Rey Auditory Verbal Learning Test (RAVLT)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2019-08-05",
      "completion_date": "2022-02-26",
      "has_results": false,
      "last_update_posted_date": "2024-02-02",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Temple, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03817931"
    },
    {
      "nct_id": "NCT01972841",
      "title": "This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder Overactive",
        "Urinary Bladder Diseases\\Urologic Diseases",
        "Overactive Bladder",
        "Urgency Incontinence"
      ],
      "interventions": [
        {
          "name": "Solifenacin succinate",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match solifenacin succinate",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Europe B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3527,
      "start_date": "2013-11-05",
      "completion_date": "2015-10-22",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 121,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01972841"
    },
    {
      "nct_id": "NCT02981459",
      "title": "Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Frequency/Urgency",
        "Bladder Irritable",
        "Bladder Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 89 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2017-12-08",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-09-26T09:13:26.306Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02981459"
    }
  ]
}